DUBLIN, May 3, 2018 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will host an educational webinar on Thursday, May 10, 2018 to discuss ALKS 3831, an investigational, novel, once-daily, oral atypical antipsychotic drug candidate for the treatment of schizophrenia. Management will present new metabolic findings, discuss ALKS 3831's proposed mechanism of action and provide an overview of the clinical development program.
Webcast Presentation and Conference Call
Alkermes will host a webcast presentation with accompanying slides on Thursday, May 10, 2018, at 8:30 a.m. ET (1:30 p.m. BST), to discuss ALKS 3831 for the treatment of schizophrenia. The webcast player may be accessed on the Investors section of Alkermes' website at www.alkermes.com. To participate in the question and answer session, please also dial in to the conference call, which may be accessed by dialing +1 888 424 8151 for U.S. callers and +1 847 585 4422 for international callers. The conference call ID number is 6037988. The webcast presentation will be archived on the Investors section of the Alkermes website for at least 90 days.
About ALKS 3831
ALKS 3831 is an investigational, novel, once-daily, oral atypical antipsychotic drug candidate for the treatment of schizophrenia. ALKS 3831 is composed of samidorphan, a novel, new molecular entity co-formulated with the established antipsychotic agent, olanzapine, in a single bilayer tablet.
Weight gain is a common and clinically relevant metabolic side effect of atypical antipsychotic medications, and olanzapine, commercially available as ZYPREXA®, has one of the highest incidences and greatest amounts of weight gain among the widely prescribed products in this class of drugs.1 ALKS 3831 is designed to provide the strong antipsychotic efficacy of olanzapine and a differentiated safety profile with favorable weight and metabolic properties.
About Alkermes plc
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
ZYPREXA® is a registered trademark of Eli Lilly & Company.
1Komossa, K. et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews. 2010, Issue 3. Art. No.: CD006654.
Alkermes Contacts:
For Investors: Eva Stroynowski, +1 781 609 6823
Sandy Coombs, +1 781 609 6377
For Media: Jennifer Snyder, +1 781 609 6166
View original content with multimedia:http://www.prnewswire.com/news-releases/alkermes-to-host-webcast-and-conference-call-to-discuss-alks-3831-development-program-300642186.html
SOURCE Alkermes plc
